文献速递腹部介入CTMR

肝细胞癌中NRF2失调与缺血:队列研究和实验室研究

NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation.
PubMed 文献 · Radiology · 2020-08-11

研究纳入65例接受经导管动脉栓塞(TAE)的肝细胞癌患者并联合HCC细胞系实验,发现NRF2通路突变的HCC在TAE后局部进展时间更短(6个月累积发生率56% vs 22%,P < .001),细胞系证实NRF2过表达导致缺血抵抗;但缺血与NRF2抑制(shRNA敲低或ML385)协同抑制NRF2过表达细胞增殖,提示缺血同时诱导对NRF2抑制的敏感性。

要点

  • NRF2通路突变的HCC在TAE后6个月局部进展累积发生率为56%,高于无突变者的22%(P < .001)。
  • NRF2过表达HCC细胞系证实存在缺血抵抗,缺血与NRF2敲低或ML385协同抑制细胞增殖。
  • ML385剂量反应曲线显示缺血诱导NRF2改变细胞对NRF2的依赖。

核心结论

  • NRF2改变的肝细胞癌对缺血表现出抵抗,但缺血同时诱导对NRF2抑制的敏感性。

研究设计与样本

  • 回顾性机构数据库审查(2011年1月至2018年12月)联合前瞻性研究(2014年1月至2018年12月)纳入接受TAE的HCC患者,并行HCC细胞系实验室研究。
  • 共纳入65例患者(中位年龄69岁,范围19-84岁;53例男性)。
  • 影像随访包括术后1个月肝脏CT或MRI,之后每3个月复查;肿瘤影像学反应基于随访影像评估。
  • 采用竞争风险分析(Gray检验)估计NRF2通路改变与无改变患者TAE后局部进展时间。
  • 体外评估四种HCC细胞系(含或不含NRF2过表达)对缺血的反应,并测试缺血联合shRNA敲低NRF2或NRF2抑制剂的效果;进行倍增时间估计、剂量反应曲线回归和比较分析。

关键影像表现/征象

  • NRF2通路突变的HCC在TAE后局部进展时间短于无突变者,6个月局部进展累积发生率为56%(范围19%-91%)vs 22%(范围12%-34%),P < .001。

诊断标准与关键数值

  • 影像学肿瘤反应基于术后1个月及之后每3个月的CT或MRI随访评估。
  • 局部进展时间采用竞争风险分析(Gray检验)估计,6个月局部进展累积发生率NRF2突变组56%(范围19%-91%),无突变组22%(范围12%-34%),P < .001。

临床应用与阅片要点

  • 对于拟行TAE的中间期HCC,NRF2通路突变者TAE后局部进展风险较高,6个月累积发生率达56%。
  • 实验室结果显示缺血与NRF2抑制(shRNA敲低或ML385)协同抑制NRF2过表达HCC细胞增殖,ML385剂量反应曲线提示缺血诱导细胞对NRF2的依赖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Intermediate stage hepatocellular carcinomas (HCCs) are treated by inducing ischemic cell death with transarterial embolization (TAE) or transarterial chemoembolization (TACE). A subset of HCCs harbor nuclear factor E2-related factor 2 (NRF2), a major regulator of the oxidative stress response implicated in cell survival after ischemia. NRF2-mutated HCC response to TAE and/or TACE is unknown. Purpose To test whether ischemia resistance is present in individuals with NRF2-mutated HCC and if this resistance can be overcome by means of NRF2 inhibition in HCC cell lines. Materials and Methods This was a combined retrospective review of an institutional database (from January 2011 to December 2018) and prospective study (from January 2014 to December 2018) of participants with HCC who underwent TAE and a laboratory investigation of HCC cell lines. Imaging follow-up included liver CT or MRI at 1 month after the procedure followed by 3-month interval scans. Tumor radiologic response was assessed on the basis of follow-up imaging. The time to local progression after TAE for individuals with and individuals without NRF2 pathway alterations was estimated by using competing risk analysis (Gray test). The in vitro response to ischemia in four HCC cell lines with and without NRF2 overexpression was evaluated, and the combination of ischemia with NRF2 knockdown by means of short hairpin RNA or an NRF2 inhibitor was tested. Doubling time estimates, dose response curve regression, and comparison analyses were performed. Results Sixty-five individuals (median age, 69 years [range, 19-84 years]; 53 men) were evaluated. HCCs with NRF2 pathway mutation had a shorter time to local progression after TAE compared to those without mutation (6-month cumulative incidence of local progression, 56% [range, 19%-91%] vs 22% [range, 12%-34%], respectively; P < .001) and confirmed ischemia resistance in NRF2-overexpressing HCC cell lines. However, ischemia and NRF2 knock-down worked synergistically to decrease proliferation of NRF2-overexpressing HCC cell lines. Dose response curves of ML385, an NRF2 inhibitor, showed that ischemia induces addiction to NRF2 in cells with NRF2 alterations. Conclusion Hepatocellular carcinoma with nuclear factor E2-related factor 2 (NRF2) alterations showed resistance to ischemia, but ischemia simultaneously induced sensitivity to NRF2 inhibition. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Weiss and Nezami in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ziv E, Zhang Y, Kelly L, et al. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology. 2020. PMID: 32780006. doi:10.1148/radiol.2020200201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。